Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki MJ, Oberg K, Knigge U. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49:740-56.
https://www.ncbi.nlm.nih.gov/pubmed/20553100

Joseph S, Wang YZ, Boudreaux JP, Anthony LB, Campeau R, Raines D, O'Dorisio T, Go VL, Vinik AI, Cundiff J, Woltering EA. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin North Am 2011;40:205-31.
https://www.ncbi.nlm.nih.gov/pubmed/21349420

Parus JL, Mikolajczak R. Beta-emitting radionuclides for peptide receptor radionuclide therapy. Curr Top Med Chem 2012;12:2686-93.
https://www.ncbi.nlm.nih.gov/pubmed/22918775

Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii124-30. 
https://www.ncbi.nlm.nih.gov/pubmed/22997445

van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007a;46:723-34.
https://www.ncbi.nlm.nih.gov/pubmed/17653893

Kwekkeboom DJ, De Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, and Krenning EP (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 26(13): 2124–2130.
https://www.ncbi.nlm.nih.gov/pubmed/18445841

Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78-88.
https://www.ncbi.nlm.nih.gov/pubmed/20113677

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer 2011;18(Suppl 1):S27-51.
https://www.ncbi.nlm.nih.gov/pubmed/22005114

Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, Zhang H. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. Biomed Res Int 2013;2013:102819.
https://www.ncbi.nlm.nih.gov/pubmed/24106690

van Vliet EI, Teunissen JJ, Kam BL, de Jong M, Krenning EP, Kwekkeboom DJ. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. Neuroendocrinology 2013a;97: 74-85. 
https://www.ncbi.nlm.nih.gov/pubmed/22237390

Forrer F, Riedweg I, Maecke HR, and Mueller-Brand J (2008). Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 52: 334–340.
https://www.ncbi.nlm.nih.gov/pubmed/18480742

Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QKT, Mäcke HR, Müller-Brand J, Rochlitz C, Briel M, Schindler C, and Walter MA (2014). Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 41(2): 214–222.
https://www.ncbi.nlm.nih.gov/pubmed/24085501

Baum RP, Kluge A, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, and Van Echteld C, (2016). [177Lu-DOTA]0-D-Phe1-Tyr3-octreotide (177Lu-DOTATOC) for Peptide Receptor Radiotherapy in patients with advanced Neuroendocrine Tumors: A retrospective Phase II study of efficacy and safety. Theranostics). 6(4):501-510.
https://www.ncbi.nlm.nih.gov/pubmed/26941843

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, and Baum RP (2013). The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent results in cancer research. 194: 519–536.
https://www.ncbi.nlm.nih.gov/pubmed/22918780